Free Trial

NKGen Biotech (NKGN) Competitors

NKGen Biotech logo
$0.02 +0.01 (+81.82%)
As of 02:14 PM Eastern

NKGN vs. UPC, REVB, ARTL, DRMA, VRAX, SRNE, GTBP, ADTX, PWUP, and PRFX

Should you be buying NKGen Biotech stock or one of its competitors? The main competitors of NKGen Biotech include Universe Pharmaceuticals (UPC), Revelation Biosciences (REVB), Artelo Biosciences (ARTL), Dermata Therapeutics (DRMA), Virax Biolabs Group (VRAX), Sorrento Therapeutics (SRNE), GT Biopharma (GTBP), Aditxt (ADTX), PowerUp Acquisition (PWUP), and PainReform (PRFX). These companies are all part of the "pharmaceutical products" industry.

NKGen Biotech vs. Its Competitors

Universe Pharmaceuticals (NASDAQ:UPC) and NKGen Biotech (NYSE:NKGN) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.

Universe Pharmaceuticals has higher revenue and earnings than NKGen Biotech.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Universe Pharmaceuticals$19.29M0.14-$8.73MN/AN/A
NKGen BiotechN/AN/A-$82.94M-$1.72-0.01

Company Net Margins Return on Equity Return on Assets
Universe PharmaceuticalsN/A N/A N/A
NKGen Biotech N/A N/A -479.36%

0.2% of Universe Pharmaceuticals shares are owned by institutional investors. Comparatively, 76.2% of NKGen Biotech shares are owned by institutional investors. 57.4% of Universe Pharmaceuticals shares are owned by company insiders. Comparatively, 10.4% of NKGen Biotech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Universe Pharmaceuticals' average media sentiment score of 0.00 equaled NKGen Biotech'saverage media sentiment score.

Company Overall Sentiment
Universe Pharmaceuticals Neutral
NKGen Biotech Neutral

Universe Pharmaceuticals has a beta of 1.49, indicating that its stock price is 49% more volatile than the S&P 500. Comparatively, NKGen Biotech has a beta of 1.15, indicating that its stock price is 15% more volatile than the S&P 500.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Universe Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
NKGen Biotech
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

Universe Pharmaceuticals beats NKGen Biotech on 6 of the 7 factors compared between the two stocks.

Get NKGen Biotech News Delivered to You Automatically

Sign up to receive the latest news and ratings for NKGN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NKGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NKGN vs. The Competition

MetricNKGen BiotechBiological Products IndustryMedical SectorNYSE Exchange
Market Cap$2.49M$343.89M$6.22B$21.80B
Dividend YieldN/AN/A5.74%3.61%
P/E Ratio0.00N/A28.6532.41
Price / SalesN/A491.64550.7684.89
Price / CashN/A22.4437.3824.48
Price / Book-0.013.6712.314.59
Net Income-$82.94M-$127.22M$3.33B$1.02B
7 Day PerformanceN/A-4.58%-1.74%-0.86%
1 Month PerformanceN/A5.39%4.72%-0.79%
1 Year PerformanceN/A2.64%61.14%10.17%

NKGen Biotech Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NKGN
NKGen Biotech
N/A$0.02
+81.8%
N/A-97.6%$2.49MN/A0.00N/AGap Up
UPC
Universe Pharmaceuticals
N/A$6.35
+5.8%
N/AN/A$3.38M$23.02M0.00220Gap Down
REVB
Revelation Biosciences
1.1763 of 5 stars
$1.36
+1.5%
N/A-97.1%$3.13MN/A-0.0210Short Interest ↓
ARTL
Artelo Biosciences
2.211 of 5 stars
$4.14
+0.2%
$24.00
+479.7%
-53.6%$2.91MN/A-0.225Short Interest ↑
DRMA
Dermata Therapeutics
1.6964 of 5 stars
$4.21
-0.2%
$10.00
+137.5%
-73.4%$2.88MN/A-0.268Short Interest ↑
VRAX
Virax Biolabs Group
2.6601 of 5 stars
$0.66
+1.5%
$3.00
+354.1%
-60.7%$2.83M$6.33K0.005
SRNE
Sorrento Therapeutics
1.0016 of 5 stars
$0.01
-9.1%
N/A+175.9%$2.76M$60.32M0.00800Gap Down
GTBP
GT Biopharma
2.0038 of 5 stars
$0.72
-2.4%
$11.00
+1,427.8%
-71.1%$2.62MN/A-0.188Gap Down
ADTX
Aditxt
N/A$0.48
-5.8%
N/A-99.9%$2.51M$130K0.0060News Coverage
PWUP
PowerUp Acquisition
N/A$0.32
-4.0%
N/A-97.6%$2.46MN/A0.00N/AHigh Trading Volume
PRFX
PainReform
0.9704 of 5 stars
$1.27
+5.0%
N/A-56.8%$2.44MN/A-0.014Gap Up

Related Companies and Tools


This page (NYSE:NKGN) was last updated on 10/22/2025 by MarketBeat.com Staff
From Our Partners